Search Results
Dec 10, 2025, 09:43 ET Cohen & Steers Launches Infrastructure Opportunities and Short Duration Preferred Securities Active ETFs
NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) is adding to its suite of actively managed exchange-traded funds (ETFs) with the launch of two new strategies: the Cohen & Steers Infrastructure
More news about: Cohen & Steers, Inc.
Dec 10, 2025, 09:05 ET 凌科藥業與美國 Formation Bio 就 LNK01006 達成獨家開發與許可協議
IND 批准，將在美國開展首次人體臨床試驗。Formation Bio 計劃於2026年上半年啟動Ⅰ期臨床試驗，進一步體現其在構建高潛力臨床資產組合方面不斷增強的實力。 LNK01006 是一款新一代 CNS 滲透性 TYK2 變構抑制劑，兼具強效、選擇性抑制 TYK2 介導的細胞因子信號傳導能力，並具備針對中樞免疫調節而優化的藥理特性。其潛在同類最佳的選擇性和 CNS 暴露水平旨在調節中樞神經系統內的免疫信號，有望干預多種與自身免疫及炎症性疾病相關的免疫反應。其獨特的藥理特徵還可用於探索以中樞或「局域免疫通路」為關鍵發病機制的多種潛在適應症。 「該資產是我們『Known
More news about: 凌科藥業
Dec 10, 2025, 09:05 ET Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
assets.LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate
More news about: Lynk Pharmaceuticals Co., Ltd.
Dec 10, 2025, 09:00 ET Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
assets.LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate
More news about: Formation Bio
Dec 09, 2025, 08:42 ET Mercury Bio Announces Appointment of Casey Perkins as Vice President of Corporate Strategy & Business Development
Mercury Bio, a company advancing intracellular delivery for central nervous system (CNS) therapeutics through its proprietary yEV™ platform, is pleased to announce the appointment of Cassandra "Casey" Perkins as Vice President of Corporate
More news about: Mercury Bio Inc.
Dec 09, 2025, 08:00 ET Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
medicine and Adasuve®, will be eliminated, delivering immediate cost savings and enhancing overall deal economics.In addition, two promising CNS pipeline assets targeting Parkinson's disease and Cyclic Vomiting Syndrome (CVS), both at Phase 2 clinical stage, will be integrated into the Company's
More news about: Lee's Pharmaceutical Holdings Limited
Dec 09, 2025, 06:00 ET Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD)
clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Dec 08, 2025, 16:24 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for November 2025
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $91.9 billion as of November 30, 2025, an increase of $1.3 billion from assets under management
More news about: Cohen & Steers, Inc.
Dec 08, 2025, 13:00 ET Moutai Returns to its Origin of World Fame, 110 Years from its Debut on Panama Expo
chapter.Media ContactDIAMOND HONG,INC. Address: 211-239 41st Street, Brooklyn, New York 11232 U.S.A.Tel: 001-9178683391CNS ENTERPRISES,INC. Address: 7709 Industry Ave., Pico Rivera, Ca 90660, U.S.A.Tel: 001-3109258482D & D LIQUOR AND WINE LLC Address:
More news about: Moutai
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
(Sumitomo Pharma Canada, Inc.) focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With several marketed products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage investigational assets, we aim to accelerate
More news about: Sumitomo Pharma America
Dec 08, 2025, 10:00 ET Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond
potential to redefine treatment for diseases caused by pathogenic multimeric proteins. Together with Qiming, we will expand our expertise in TPD and CNS drug development, accelerate our pipeline toward clinical proof-of-concept, and deliver on our mission to help patients with limited treatment options." Dr.
More news about: Convergen
Dec 08, 2025, 08:30 ET Cohen & Steers Named a "Best Place to Work in Money Management" by Pensions & Investments for Sixth Consecutive Year
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that it has been named as one of the "Best Places to Work in Money Management" for the sixth consecutive year by Pensions & Investments,
More news about: Cohen & Steers, Inc.
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
Brain Sci. 2020;10(2):107.7 Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.8 Leonard H, et al. CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol.
More news about: UCB
Dec 08, 2025, 05:35 ET Exosomes Market Led by North America with 53% Revenue Share and Global Market Size Set to Surpass USD 2B by 2030, Says Mordor Intelligence
Epigenetics Market: The epigenetics market is segmented by product (instruments, reagents & kits), application (oncology, neurology & CNS disorders, metabolic diseases, autoimmune diseases), technology (dna methylation analysis, histone modification-acetylation, methylation), and geography
More news about: Mordor Intelligence Private Limited
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla® EU SmPC.
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla® EU SmPC.
More news about: UCB
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1) designed to inhibit the spread of SOD1 pathology in the CNS of ALS patients. AP-101 received orphan drug designations from FDA, EMA and Swissmedic. The Phase 2 study evaluated safety, tolerability, pharmacodynamic
More news about: AL-S Pharma AG
Dec 05, 2025, 12:46 ET Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
Use of Emapalumab is associated with rapid and sustained benefits in pHLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-050105 and NI-050109.
More news about: Swedish Orphan Biovitrum AB
Dec 05, 2025, 09:00 ET NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.Suicidal Behavior and Ideation:Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts
More news about: Jazz Pharmaceuticals plc
Dec 04, 2025, 09:00 ET Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting
digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today presented new analysis from its CNS-101 study at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, California.
More news about: Cumulus Neuroscience
Dec 04, 2025, 08:12 ET UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening. NAYZILAM may cause an increased CNS-depressant effect when used with alcohol or other CNS depressants. Concomitant use with moderate or strong CYP3A4 inhibitors may result in prolonged sedation due to a decrease
More news about: UCB
Dec 04, 2025, 07:00 ET SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer
of disease pathways including Lp-PLA21, beta amyloid and LRRK22 as well as the ongoing discovery of novel treatments for other CNS disorders.
More news about: SciNeuro Pharmaceuticals
Dec 04, 2025, 07:00 ET Neurimmune expands collaboration with AstraZeneca to develop and commercialize fibril depleter NI009 for AL amyloidosis
biopharmaceutical company building next generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered
More news about: Neurimmune
Dec 04, 2025, 04:42 ET Generic Injectables Market Dominated by Hospital Pharmacies with 61.23% Share as Online Pharmacies Surge at 18.06% CAGR Through 2030, Reports Mordor Intelligence
Generics By Therapeutic Area Oncology Anti-infectives Cardiovascular Diabetes & Metabolic CNS Disorders Others By Route of Administration Intravenous Intramuscular Sub-cutaneous Others By
More news about: Mordor Intelligence Private Limited